Skip to content
EMBARC
Menu
  • HOME
  • ABOUT US
    • Management Committee
    • Industry Partners
    • Acknowledgements
    • EMBARC Members
    • Transparency Notice
  • News
  • RESEARCH
    • The European Bronchiectasis Registry
    • The Biobank i.e., The EMBARC-BRIDGE Study
    • Clinical Trials
      • GREAT-2
      • AIR-NET
      • ESCAPE
      • Support of Non-EMBARC Clinical Trials
    • The Bronchiectasis Genetics Initiative
      • GECCO
    • Treatment Responses
      • Inhaled Antibiotics (ORBIT-3/4)
    • Imaging
    • Disease Definitions
    • Primary Ciliary Dyskinesia
    • Standards of Care
    • Patient Reported Outcomes
      • Chronic Airways Assessment Test (CAAT)
      • Bronchiectasis Health Questionnaire (BHQ)
      • Licensing for use of PROMs
    • Publications
  • EDUCATION
    • Early Careers Area
    • Treatment Guidelines
    • For Respiratory Professionals
      • Severity Assessment Calculator
    • For General Practitioners
  • PATIENT AREA
    • Patient Conference
  • EMBARC REGISTRY
  • Contact Us
Study Overview
Sign up to EMBARC-BRIDGE today!
Essential Documentation
Study Overview

BACKGROUND:

The Bronchiectasis Research Involving Databases, Genomics and Endotyping (BRIDGE) study represents an observational, multicentre, mechanistic sub-study conducted through the EMBARC consortium (NCT03791086) (Aliberti et al., 2018).

STUDY AIMS & OBJECTIVES:

The study’s primary aim is to phenotype and endotype bronchiectasis patients during stable disease and periods of exacerbation to delineate the underlying mechanisms driving disease, with the hope of developing strategies for personalised medicine and guiding treatment response.

The BRIDGE study also has the following secondary aims:

  1. To identify molecular endotypes of bronchiectasis during periods of disease stability.
  2. To identify the causes of, and better understand the inflammatory component of, bronchiectasis exacerbations.
  3. To identify and validate biomarkers of disease with potential use in personalised medicine.
  4. To generate proof-of-concept data by in vivo and in vitro studies to identify subsets of patients likely to benefit in upcoming randomised controlled trials.

SAMPLE COLLECTION:

BRIDGE collects both clinical data and biological samples at recruitment with annual (± 3 months) follow-up data collected for up to 3 years following initial recruitment – 4 study visits in total.

A summary of the biological samples collected are shown below.

STUDY RECRUITMENT:

Patient enrolment into the BRIDGE study began in January 2019 with recruitment currently ongoing (NCT03791086).

As of February 2025, we have recruited 1,476 patients into BRIDGE.

We currently have 26 research sites taking part in the EMBARC-BRIDGE study (red), with additional sites in set up (yellow).

These include:

UK (Dundee, Fife, Newcastle, Manchester x 2, London, Cambridge, Bristol x 2)

Ireland (Dublin)

Italy (Milan x 2)

Spain (Barcelona x 2, Valencia)

Portugal (Porto, Gondomar)

Germany (Hannover, Muenster)

The Netherlands (Amsterdam)

Belgium (Leuven)

Greece (Athens)

Israel (Haifa) 

South Korea (Seoul)

North Macedonia

Poland (Warsaw)

Sign up to EMBARC-BRIDGE today!

If you are a research site interested in contributing data/samples to the EMBARC-BRIDGE study, please register your interest here.

Essential Documentation

BRIDGE Protocol V4 24.01.24

BRIDGE Protocol Receipt V4 24.01.24

BRIDGE Letter of invitation V2 26.01.24

BRIDGE Participant Information Sheet V3 24.01.24

BRIDGE Informed Consent Form V2 21.03.24

BRIDGE Cilia sub-study Participation Information Sheet V2 24.01.24

BRIDGE Cilia sub-study Informed Consent Form V2 24.01.24

BRIDGE GP and Clinic Letter V2 26.01.24

BRIDGE BIM Baseline questionnaire, V2.0, 24-04-2019

BRIDGE BIM Follow-up questionnaire, V2.0, 24-04-2019

QOL-B with Demographics v3.1

Questionnaire QOL-B, Scoring Instructions V1 12-09-2018

CAAT Patient Questionnaire_updated

Bridge Questionnaire BHQ, V1, 24-04-2019

 
Copyright EMBARC ©2025
Web Site Supported by HIC Services & University of Dundee ©2025
Youtube Linkedin